GlassScriptPhysician profile
William K Dehart
NPI 1194936799
$20,800.08
in general payments reported to CMS, 2019-2025
29 companies · $4,263 in 2025
The $4,263 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $1,174 · 2021: $1,260 · 2022: $3,325 · 2023: $4,333 · 2024: $4,938 · 2025: $4,263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,558 · Food and Beverage: $3,895 · Honoraria: $2,750 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $873 · Travel and Lodging: $459.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,557.50 |
| Food and Beverage | $3,894.77 |
| Honoraria | $2,750.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $872.81 |
| Travel and Lodging | $459.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $4,374.56 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $3,035.10 | 2022-2024 | Sotyktu |
| Abbvie INC. | $3,022.82 | 2019-2025 | Rinvoq, Skyrizi |
| Lnhc, INC | $2,884.26 | 2025 | Zelsuvmi |
| Galderma Laboratories, L.P. | $2,211.56 | 2019-2025 | Nemluvio, Aklief |
| Janssen Biotech, INC. | $678.76 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Pfizer INC. | $623.22 | 2019-2024 | |
| Genzyme Corporation | $567.74 | 2019-2025 | |
| Arcutis Biotherapeutics, INC. | $449.96 | 2023-2025 | Zoryve |
| Sun Pharmaceutical Industries INC. | $447.11 | 2019-2025 | Odomzo, Blu-U |
| Leo Pharma INC. | $387.22 | 2019-2024 | Adbry |
| Ucb, INC. | $318.57 | 2019-2021 | |
| Amgen INC. | $308.47 | 2019-2025 | Otezla, Otezla, Enbrel |
| Lilly USA, LLC | $217.40 | 2019-2024 | Olumiant, Taltz |
| Biofrontera INC. | $192.80 | 2021-2024 | Ameluz, Xepi, Bf-Rhodoled |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Botanix Sb INC | $159.17 | 2025 | Sofdra |
| Regeneron Healthcare Solutions, INC. | $155.25 | 2019-2022 | |
| Dermavant Sciences, INC. | $153.74 | 2022-2024 | Vtama |
| Vyne Pharmaceuticals INC. | $118.58 | 2020 | |
| Epi Health, LLC | $109.51 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $103.54 | 2019-2021 | |
| Incyte Corporation | $64.10 | 2022-2025 | Opzelura |
| Organon LLC | $54.30 | 2024-2025 | Vtama |
| Verrica Pharmaceuticals INC. | $39.94 | 2023 | Ycanth |
| Dermira, INC. | $36.44 | 2019-2020 | |
| Strata Skin Sciences, INC. | $29.90 | 2019 | |
| Genentech USA, INC. | $22.68 | 2019 | |
| Mayne Pharma Commercial LLC | $18.44 | 2019 | |
| Merck Sharp & Dohme LLC | $14.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dehart listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.